Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 13/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8625960 | 0.90 | HTT (0.49) | PTGER1HTTSMN1; SMN2LMNAMAPT | |
| SCHEMBL8629304 | 0.90 | PTGER1 (0.52) | PTGER1HTTSMN1; SMN2LMNAMAPT | |
| SCHEMBL4703021 | 0.85 | SMN1; SMN2 (0.62) | HTTSMN1; SMN2LMNAMAPTL3MBTL1 | |
| SCHEMBL1508856 | 0.85 | KMT2A (0.47) | PTGER1HTTSMN1; SMN2LMNAMAPT | |
| SCHEMBL27610351 | 0.83 | PTGER1 (0.43) | PTGER1HTTSMN1; SMN2LMNAMAPT | |
| SCHEMBL6567431 | 0.82 | PTGER1 (0.47) | PTGER1HTTSMN1; SMN2LMNAMAPT | |
| SCHEMBL8628854 | 0.80 | HTT (0.49) | PTGER1HTTSMN1; SMN2LMNAMAPT | |
| SCHEMBL6567174 | 0.80 | GAA (0.45) | PTGER1HTTSMN1; SMN2LMNAMAPT | |
| SCHEMBL31645370 | 0.80 | IKBKB (0.49) | PTGER1HTTSMN1; SMN2LMNAMRGPRX4 | |
| SCHEMBL30165558 | 0.78 | PTGER1 (0.45) | PTGER1HTTSMN1; SMN2LMNASTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0765871-B1 | Substituted Quinoline-2-carboxamides, their preparation and their use as prolyle-4-hydroxylase Inhibitors | FIBROGEN INC (US) | 2004-03-31 | — | — | EP | disclosed |
| CN-1120157-C | Substituted quinoline-2-carboxamides, process for their preparation and their use as pharmaceuticals, and intermediates thereof | FIBER GENE CORP (US) | 2003-09-03 | — | — | CN | disclosed |
| US-6329497-B1 | ANTITUMOR AGENTS; VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS | THE SCRIPPS RESEARCH INSTITUTE | 2001-12-11 | — | — | US | disclosed |
| EP-0996458-A4 | SANDRAMYCIN ANALOGS | SCRIPPS RESEARCH INST (US) | 2001-05-02 | — | — | EP | disclosed |
| CN-1282737-A | Intermediate product used for preparing substituted quinoline-2-formamide | MOECHST AG (DE) | 2001-02-07 | — | — | CN | disclosed |
| EP-0996458-A1 | SANDRAMYCIN ANALOGS | The Scripps Research Institute (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1998043663-A1 | SANDRAMYCIN ANALOGS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-10-08 | — | — | WO | disclosed |
| US-5726305-A | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-03-10 | — | — | US | disclosed |
| US-5719164-A | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-02-17 | — | — | US | disclosed |
| CN-1154365-A | Substituted quinoline-2-carboxamides, process for their preparation and their use as pharmaceuticals, and intermediates thereof | HOECHST AG (DE) | 1997-07-16 | — | — | CN | disclosed |
| EP-0765871-A1 | Substituted Quinoline-2-carboxamides, their preparation and their use as prolyle-4-hydroxylase Inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-04-02 | — | — | EP | disclosed |